Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Pulmonary Hypertension
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Giessen Pulmonary Hypertension Registry and Biobank

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Survival (Up to 20 years after enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 1993-07
Completion: 2036-01-15
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Giessen
Principal Investigators:
  • Khodr Tello, MD (PRINCIPAL_INVESTIGATOR) - University Clinics of Giessen and Marburg
Contact Information
Study Contact:
Khodr Tello, MD
0641/985-51250
khodr.tello@innere.med.uni-giessen.de
Khodr Tello, MD
0641/985-51250
khodr.tello@innere.med.uni-giessen.de
Department of Intermal Medicine - Universities of Giessen and Marburg Lung Center
Interventions
N/A
Study Locations (1 sites)
Department of Intermal Medicine - Universities of Giessen and Marburg Lung Center, Giessen, 35392 Germany
Eligibility Criteria
Inclusion Criteria: * Right heart catheterization for PH diagnosis in Giessen Exclusion Criteria: * informed consent missing
Conditions MASH, MASLD, MASH With Fibrosis, Fibrosi...
Phase Not Applicable
Enrollment 10000
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and to raise awareness. The primary objective is to implement a transmural patient care pathway, in order to identify patients with MASLD and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) in primary care centres and clinics in 10 European countries.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Prevalence of liver steatosis and MASLD estimated by FibroScan CAP in patients at risk (Baseline)
  • Prevalence of liver fibrosis estimated by FibroScan LSM in patients at risk (Baseline)
  • Prevalence of at-risk MASH estimated by FAST score in patients at risk (Baseline)
  • *Subset of patients: prevalence of MASH in patients at risk (16 or 30 weeks)
  • Comparison of the prevalence of MASLD, liver fibrosis and (at-risk) MASH between the participating countries (Baseline (1-3) to 16/30 weeks for biopsy-confirmed MASH (4))
  • Evaluate added value of a 2-step pathway as compared to FibroScan only for detection of high-risk patients (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-06-30
Completion: 2031-03-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Julius Clinical
Collaborators: UMC Utrecht, Echosens, MIMETAS BV, Nordic Bioscience A/S, Elevate BV, Leiden University, Amsterdam University Medical Center, Andaluz Health Service, National Research Council, Institute of Clinical Physiology, Italy, Leiden University Medical Center, Université Libre de Bruxelles, University Hospital, Antwerp, Catholic University of the Sacred Heart, Medical Education Research And Innovation Center S.R.L., European Liver Patients' Association, Harokopio University, General University Hospital, Prague, Novo Nordisk A/S, Maastricht University, Mercodia Aktiebolag, EXIT071 BV, European Atherosclerosis Society, MetaDeq Limited, Associação para Investigação e Desenvolvimento da Faculdade de Medicina, Institute of Cardiometabolism and Nutrition, France, University Hospital, Saarland, Roche Pharma AG, Inventiva Pharma, Biocellvia, Franciscus Gasthuis & Vlietland (Hospital)
Principal Investigators:
  • Manuel Castro Cabezas, MD/PhD (PRINCIPAL_INVESTIGATOR) - Sint Franciscus Gasthuis
  • Diederick E. Grobbee, MD/PhD/FESC (PRINCIPAL_INVESTIGATOR) - UMC Utrecht
  • Oscar H. Franco, MD/PhD/FESC/FFPH (STUDY_CHAIR) - UMC Utrecht
Contact Information
Study Contact:
de Jong
+31628259968
griponmash@juliusclinical.com
Wijkhuis
griponmash@juliusclinical.com
Interventions
N/A
Study Locations (13 sites)
Hôpital Erasme, Cliniques Universitaires De Bruxelles, Brussels, Vlaams-brabant B-1070 Belgium
Antwerp University Hospital, Antwerp, B-2650 Belgium
4th internal clinic General University Hospital, Prague, Bohemia 128 08 Czechia
Hôpital de la Pitié Salpêtrière, Paris, Il-de-France 75013 France
Universitätsmedizin Mainz, Mainz, Rhineland-Palatinate 55131 Germany
Universitätsklinikum des Saarlandes, Homburg, Saarland 66421 Germany
Harokopio University of Athens, Athens, 17676 Greece
Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG), Università Cattolica del Sacro Cuore (UCSC), Rome, Lazio 00168 Italy
Amsterdam UMC, Amsterdam, South Holland 1105 AZ Netherlands
Franciscus Gasthuis & Vlietland, Rotterdam, South Holland 3045 PM Netherlands
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed subjects should fulfil criteria for diagnosis of type 2 diabetes mellitus or metabolic syndrome or obesity or arterial hypertension, following the study definitions. * Subjects that are currently being treated for type 2 diabetes mellitus or metabolic syndrome or obesity or arterial hypertension, should have had a prior diagnosis based on study definitions. Study definitions: Type 2 diabetes mellitus * At least 2 times a fasting glucose \> 7,0 mmol/L * Or elevated non-fasting glucose \>11,1 mmol/L 2 hrs after OGTT * Or HbA1c ≥48 mmol/mol (≥6.5%) * Or being actively treated for previously diagnosed type 2 diabetes by a health care provider Obesity * Body mass index (BMI) \> 30 * Or waist circumferences Caucasian: male ≥ 94 cm, female ≥ 80 cm South-Asian/Chinese: male ≥90 cm, female ≥80 cm Japanese: male ≥85 cm, female ≥90 cm Arterial hypertension * Systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg * Or being actively treated for previously diagnosed arterial hypertension by a health care provider Metabolic syndrome \- Central obesity defined as waist circumference (see above), if BMI is \>30 kg/m2, central obesity can be assumed and waist circumference does not need to be measured AND any two of the following: * Raised triglycerides: ≥ 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid abnormality * Reduced HDL cholesterol: \< 40 mg/dL (1.03 mmol/L) in males, \< 50 mg/dL (1.29 mmol/L) in females, or specific treatment for this lipid abnormality * Raised blood pressure (BP): systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, or treatment of previously diagnosed hypertension * Raised fasting plasma glucose (FPG): FGP ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes (if above \>5.6 mmol/L or 100 mg/dL, an oral glucose tolerance test is strongly recommended, but is not necessary to define presence of the syndrome) Exclusion Criteria: * The patient is known with hepatitis B, C or HIV or any other liver condition (like hemochromatosis, sarcoidosis, Wilson's disease etc); * The patient is known with any other condition that may lead to liver fibrosis or cirrhosis; * The patient engages in (excessive) alcohol use: \> 3 units/day in males \[30 grams/day\] and \> 2 units/day in females \[20 grams/day\]; * The patient has a history or evidence of any other clinically significant condition or planned or expected procedure that in the opinion of the Investigator, may compromise the patient's safety or ability to be included in this study; * The patient is an employee or contractor of the facility that is conducting the study or is a family member of the Investigator, sub-Investigator, or any Sponsor personnel; * The patient is not able to understand the details of the protocol and/or is not able to provide written informed consent; * The patient is pregnant or breastfeeding. * The patient underwent bariatric surgery in the last 12 months.
Conditions Glaucoma, Glaucoma, Open-Angle
Phase NA
Enrollment 243
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the comparative efficacy and safety of Hydrus Microstent, incisional goniotomy, and excisional goniotomy when combined with cataract surgery in patients with mild and moderate open-angle glaucoma. The main questions it aims to answer are: * How do the intraocular pressure lowering effects of these three microinvasive glaucoma surgeries compare? * How do the safety profiles of these three microinvasive glaucoma surgeries compare? Participants will be randomized to one of these three microinvasive glaucoma surgeries in combination with cataract surgery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Hydrus Microstent — Patients will have a Hydrus Microstent inserted into the canal of Schlemm at the time of cataract surgery
  • Procedure: Incisional goniotomy — Patients will have incisional goniotomy to open the trabecular meshwork with a Sinskey hook at the time of cataract surgery
  • Procedure: Excisional goniotomy — Patients will have excisional goniotomy to remove the trabecular meshwork with a Kahook Dual Blade at the time of cataract surgery

Primary Outcomes

  • Intraocular pressure (3 years)
  • Intraocular pressure-lowering medications (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-14
Completion: 2029-04
Eligibility
Age: 40 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 243 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts Eye and Ear Infirmary
Contact Information
Study Contact:
Michael M Lin, MD
617-573-3707
michael_lin@meei.harvard.edu
Michael Lin, MD
617-573-3707
michael_lin@meei.harvard.edu
Massachusetts Eye and Ear
Michael Lin, MD
Massachusetts Eye and Ear
Interventions
  • Procedure: Hydrus Microstent — Patients will have a Hydrus Microstent inserted into the canal of Schlemm at the time of cataract surgery
  • Procedure: Incisional goniotomy — Patients will have incisional goniotomy to open the trabecular meshwork with a Sinskey hook at the time of cataract surgery
  • Procedure: Excisional goniotomy — Patients will have excisional goniotomy to remove the trabecular meshwork with a Kahook Dual Blade at the time of cataract surgery
Study Locations (1 sites)
Massachusetts Eye and Ear, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: * Visually significant cataract planned for surgery * Mild to moderate open-angle glaucoma, including pigmentary glaucoma and pseudoexfoliation glaucoma * Mild stage glaucoma includes glaucomatous optic neuropathy and visual field mean deviation better than -6.0 dB, with no points in the central 5 degrees \<15 dB * Moderate stage glaucoma includes: 1) glaucomatous optic neuropathy and visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5 degree points \<15 dB or 2) mean deviation -12.0 dB or better with 1 central 5 degree point \<15 dB * Medicated IOP between 10 to 31 mm Hg, inclusive, at time of decision for surgery * Willing and able to understand and provide informed consent * Willing and able to attend postoperative examinations per protocol schedule Exclusion Criteria: * Prior argon laser trabeculoplasty, laser peripheral iridotomy, incisional glaucoma surgery, or cyclophotocoagulation * Selective laser trabeculoplasty within 90 days of study enrollment * Iridotrabecular contact for 180 degrees or greater * Peripheral anterior synechiae in nasal or inferior angle * Best corrected visual acuity worse than 20/200 * Phacodonesis on pre-operative examination * Vitreous in anterior chamber on pre-operative examination * Nanophthalmos * Anti-platelet and anticoagulant medications other than aspirin 81mg daily * Active treatment for another ophthalmic condition in either eye (e.g., anti-VEGF injections, steroids for corneal transplant) * Abnormality in study eye that could affect tonometry * Glaucoma diagnosis other than the above * Normal tension glaucoma * Conditions that can cause elevated episcleral venous pressure (e.g., Sturge-Weber syndrome, Graves disease, retrobulbar tumor) * History of uveitis in either eye * Inability to complete gonioscopy examination * Use of oral steroids within 90 days or anticipated use of oral steroids * Oral medications that can affect IOP, including oral carbonic anhydrase inhibitors such as acetazolamide and methazolamide * History of steroid-associated IOP elevation * Medically unfit for attending planned study visits * Involvement in another interventional research study
Conditions Congenital Diaphragmatic Hernia
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Congenital diaphragmatic hernia (CDH) occurs when the diaphragm fails to fully fuse and leaves a portal through which abdominal structures can migrate into the thorax. In the more severe cases, the abdominal structures remain in the thoracic cavity and compromise the development of the lungs. Infants born with this defect have a decreased capacity for gas exchange; mortality rates after birth have been reported between 40-60%. Now that CDH can be accurately diagnosed by mid-gestation, a number of strategies have been developed to repair the hernia and promote lung tissue development. Fetal tracheal occlusion (FETO), using a fetoscopically delivered and removed balloon device, has been used to temporarily occlude the trachea and increase lung distension in CDH to allow the lungs to develop and has been shown to increase survival at birth. The role of FETO in the resolution of pulmonary hypertension in fetuses with severe left- and right- sided CDH remains unclear. Our recent observation that FETO is associated with a higher proportion of infants who resolve their pulmonary hypertension by the age of 1 year as compared with those who have not had FETO, is based on a retrospective cohort study, which, as with any such design, has some intrinsic limitations. Thus, a prospective cohort study that is appropriately powered to confirm or disprove this encouraging observation is needed. If our preliminary observation is confirmed, resolution of PH by the age of 1 year could be added to the benefits of the FETO procedure in severe left and right-sided CDH cases. The investigators will perform 40 FETO procedures on fetuses diagnosed prenatally with severe right- or left-sided CDH, and outcome data will be compared with that of a control group of severe right- or left-sided CDH who will not undergo the FETO procedure because of medical or social issues. Because the prevalence of left-sided CDH is higher than right-side CDH, the investigators will perform 25 FETO procedures in left sided CDH and 15 in right-sided CDH, and these outcomes will be compared to a cohort of 40 non FETO cases.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Goldbal Detachable Balloon and delivery microcatheter — Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.

Primary Outcomes

  • Resolution of Pulmonary Hypertension - 6 months (by the age of 6 months)
  • Resolution of Pulmonary Hypertension - 12 months (by the age of 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-08-09
Completion: 2030-12
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Michael A Belfort
Collaborators: Baylor College of Medicine
Principal Investigators:
  • Michael Belfort, MD PhD (PRINCIPAL_INVESTIGATOR) - Baylor College of Medicine
Contact Information
Study Contact:
Michael Belfort, MD PhD
832-826-7375
belfort@bcm.edu
Rebecca M Johnson, MS
832-826-7451
rj2@bcm.edu
Michael Belfort, M.D.
832-826-7375
Texas Childrens Hospital
Interventions
  • Device: Goldbal Detachable Balloon and delivery microcatheter — Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.
Study Locations (1 sites)
Texas Childrens Hospital, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Patient is a pregnant woman between 18 and 45 years of age * Singleton pregnancy * The fetuses will be 28+0/7 to 31+6/7 weeks of gestational age * Confirmed diagnosis of severe left- or right-sided CDH of the fetus: Observed/expected total lung volume equal to or less than 0.32 with more than 21% of liver herniated into the hemithorax. (Ideally calculated between 28+0/7 and 31+6/7 weeks' gestation.) * Normal fetal echocardiogram or echocardiogram with a minor anomaly (such a small VSD) that in the opinion of the pediatric cardiologist will not affect postnatal outcome * Normal fetal karyotype or microarray * The mother must be healthy enough to have surgery * Patient and father of the baby provide signed informed consent that details the maternal and fetal risks involved with the procedure * Patient willing to remain in Houston for the duration following balloon placement until delivery. Exclusion Criteria: * Contraindication to abdominal surgery, fetoscopic surgery, or general anesthesia * Allergy to latex * Allergy or previous adverse reaction to a study medication specified in this protocol * Preterm labor, preeclampsia, or uterine anomaly (e.g., large fibroid tumor) in the index pregnancy. * Fetal aneuploidy, known structural genomic variants, other major fetal anomalies that may impact the fetal/neonatal survival or known syndromic mutation * Suspicion of major recognized syndrome (e.g. Fryns syndrome) on ultrasound or MRI * Maternal BMI \>40 * High risk for fetal hemophilia
Conditions Heart Failure With Preserved Ejection Fr...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The primary purpose of this study is to evaluate possible association of some heterogeneous circulating biomarkers and anamnestic factors of pregnancy adverse course and outcomes with the prognosis of heart failure with preserved ejection fraction. The study population includes women aged 60-74 years with history of pregnancy with duration at least 20 weeks and diagnosed heart failure with preserved ejection fraction based on algorithm HFA-PEFF. The following pregnancy complications are assessed on the initial visit: gestational hypertension, preeclampsia, gestation diabetes mellitus and recently introduced as cardiovascular disease risk factors preterm delivery, stillbirth, miscarriage. This information is collected through a questionnaire which additionally includes questions about menopause and the circumstances of its onset. The data about comorbidities, results of laboratory and instrumental tests is collected from medical records. After the interview short physical examination is performed to measure anthropometric data and objective signs of congestion. In addition, medical Research Council Scale survey is conducted to assess the subjective severity of shortness of breath and a six-minute walking test to objectively evaluate the heart failure functional class. After inclusion in the study blood sampling is performed to measure the concentration of a number of biomarkers which are recognized as prognostically significant in context of heart failure: high-sensitivity troponin I, soluble suppression of tumorigenicity 2 protein, heat shock protein 27, cystatin C. As part of the study echocardiography is also performed with evaluation of left ventricular global longitudinal strain and left atrial strain to assess systolic and diastolic myocardium function. 12 months after the initial visit, participants are contacted by telephone. The data about newly diagnosed chronic non-communicable diseases, emergency hospitalization for any cause and major adverse cardiovascular events is collected. If there is no response from the research participant, the cause, including possible hospitalization or death, is determined by telephone contact with the participant's trusted person.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Combined endpoint made up of emergency hospitalization for any cause, major adverse cardiovascular events and all-cause mortality (From the date of enrollment until the date of the first emergency hospitalization for any cause or date of any major adverse cardiovascular event or all-cause death, whichever came first, assessed up to 1 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-15
Completion: 2026-12-31
Eligibility
Age: 60 Years – 74 Years
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Medical Research Center for Therapy and Preventive Medicine
Contact Information
Study Contact:
Vasilisa Kosulina, MD
+7-996-981-40-27
vasilisa.kosulina@mail.ru
Olga Dzhioeva, MD, PhD
+7-916-614-18-21
odzhioeva@gnicpm.ru
Vasilisa Kosulina, MD
+7-996-981-49-27
vasilisa.kosulina@mail.ru
Federal State Budgetary Institution National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthсare of the Russian Federation
Interventions
N/A
Study Locations (1 sites)
Federal State Budgetary Institution National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthсare of the Russian Federation, Moscow, 101990 Russia
Eligibility Criteria
Inclusion Criteria: * Women aged 60-74 years * Heart failure with preserved ejection fraction (diagnosed by using HFA-PEFF algorithm) * History of pregnancy with duration at least 20 weeks * Willing and legally able to sign informed consent Exclusion Criteria: * History of ejection fraction less than 50% diagnosed by echocardiography * Diagnosed cognitive impairment or dementia * The state of cardiovascular disease decompensation * Exacerbation of comorbidities * The presence of chronic diseases that may affect the results of the study: ischemic heart disease (unstable angina, stable effort angina III-IV grade, previous myocardial infarction), previous Ischemic/hemorrhagic stroke, severe valvular heart diseases, cardiomyopathy, myocarditis, uncontrolled bronchial asthma or chronic obstructive pulmonary disease, terminal chronic kidney disease requiring dialysis, implanted pacemaker (including cardiac resynchronisation device, or defibrillator), active cancer, history of chemotherapy or radiation therapy to the chest area
Conditions Atrial Fibrillation (AF), Hypertension
Phase PHASE2
Enrollment 66
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Heart failure is the most important clinical endpoint event in atrial fibrillation (AF). Patients with AF complicated by heart failure have a significantly higher risk of all-cause mortality and cardiovascular mortality compared to those without heart failure. Abnormal left atrial function is an important mechanism leading to the occurrence of AF-related heart failure. Therefore, it is essential to find drugs that can improve left atrial function to prevent heart failure in patients with AF. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are important drugs for regulating metabolic abnormalities. Studies have found that these drugs also reduce the risk of new-onset AF in patients with heart failure. Thus, the investigators hypothesize that SGLT2i may be able to regulate left atrial function. This study is a multicenter randomized controlled trial using three-dimensional speckle tracking echocardiography to investigate whether SGLT2i can improve left atrial function and prevent heart failure in patients with paroxysmal AF who have hypertension and metabolic disorders, compared to placebo. The investigators also observed the effects of SGLT2i on cardiovascular and metabolic risk factors. The investigator team has a solid foundation in the field of cardiovascular metabolism, having completed the evaluation of left atrial function in paroxysmal AF using three-dimensional speckle tracking technology over the past three years. This study is the first to propose that SGLT2i can improve left atrial function in paroxysmal AF patients with metabolic abnormalities, which is of great significance for preventing heart failure in this type of AF.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: SGLT-2 inhibitors — empagliflozin (10mg qd)
  • Drug: Placebo — PLACEBO

Primary Outcomes

  • LA strain (LASI) (from enrollment to the end of treatment at 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-01
Completion: 2027-06-30
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Huashan Hospital
Collaborators: Shanghai Zhongshan Hospital, Shanghai 10th People's Hospital
Contact Information
Study Contact:
Liwen Bao, MD
86 13917073226
blw_betty@163.com
Liwen Bao, MD
86 13917073226
blw_betty@163.com
Fudan University Affiliated Huashan Hospital, Cardiology Department
Interventions
  • Drug: SGLT-2 inhibitors — empagliflozin (10mg qd)
  • Drug: Placebo — PLACEBO
Study Locations (1 sites)
Fudan University Affiliated Huashan Hospital, Cardiology Department, Shanghai, Shanghai Municipality 200036 China
Eligibility Criteria
Inclusion Criteria: * • Patients aged 18-80 years, treated in the outpatient or inpatient departments of each research center and included in the AF database. * Patients with paroxysmal AF confirmed by 12-lead electrocardiogram, 24-hour Holter monitoring, or handheld electrocardiogram devices. * Patients with hypertension who have already started antihypertensive treatment. * Patients with diabetes who have already started antidiabetic treatment, or patients with prediabetes who have not received antidiabetic treatment but have an HbA1c level within the range of 6.1-6.4% in the past three months. Exclusion Criteria: * • Atrial fibrillation caused by severe mitral stenosis. * Atrial fibrillation with severe mitral regurgitation and severe tricuspid regurgitation. * Patients who have been clinically diagnosed with heart failure (heart failure with preserved ejection fraction or heart failure with reduced ejection fraction). * Special types of cardiomyopathy: amyloid cardiomyopathy, Fabry disease, muscular dystrophy, hypertrophic obstructive cardiomyopathy, etc. * Patients with a history of myocardial infarction within the past three months. * Pregnant women.
Conditions Glaucoma, Intraocular Pressure, Primary ...
Phase NA
Enrollment 142
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to conduct a study randomizing glaucoma patients to home intra-ocular pressure (IOP) telemonitoring combined with Smart phone-based intervention (Management Paradigm I) or Smart phone-based intervention alone (Management Paradigm II), with the objectives to compare (1) Goldmann applanation tonometry (GAT) intra-ocular pressure (IOP) measurements over the entire study period (primary outcome measure) and (2) the rates of Retinal nerve fiber layer (RNFL) thinning (secondary outcome measure) between the two Management Paradigms. We hypothesize that glaucoma patients randomized to Management Paradigm I will (1) attain lower levels of intra-ocular pressure (IOP), and (2) a slower rate of Retinal nerve fiber layer (RNFL) and ganglion cell inner plexiform layer (GCIPL) thinning compared with those randomized to Management Paradigm II because of having a more precise assessment of intra-ocular pressure (IOP) to guide intra-ocular pressure (IOP)- lowering therapy would be feasible in Management Paradigm I. It aims to: to compare (1) Goldmann applanation tonometry (GAT) intra-ocular pressure (IOP) measurements over the entire study period (primary outcome measure) and (2) the rates of Retinal Nerve Fiber Layer (RNFL) thinning (secondary outcome measure) between the two Management Paradigms. Participants will asked to do, * Management Paradigm I: will be provided with an iCare Home and instructed to measure and upload 6 intra-ocular pressure (IOP) measurements weekly (2 days a week, 1 measurement in the early morning (5 am to 9 am), 1 during the mid-day (12 pm to 4 pm) and 1 in the evening (7 pm to 11pm)) to a secure server via iCare CLINIC (the number of weekly intra-ocular pressure (IOP) measurements follows the number of weekly blood pressure measurements in the HyperLink study). The morning measurement will include two readings with the first obtained in the supine position before getting out of the bed and the second obtained in the upright position right after. Patients may take additional intra-ocular pressure (IOP) measurements in supine position if they wake up in bed from sleep, as well as other times of the day, but this is not mandatory. These additional intra-ocular pressure (IOP) measurements will not be included for treatment decisions during the study period. * Management paradigm II: Patients will be treated with a topical prostaglandin analogue after baseline intra-ocular pressure (IOP) measurements.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: Home IOP telemonitoring with smart phone-based intervention — Participants use the iCare HOME rebound tonometer to perform self-measurements of intraocular pressure at home for 30 months. After a 4-week baseline period with at least 24 measurements (early morning supine and sitting, mid-day, and evening on different days), patients continue to obtain at least six IOP measurements per week and upload readings to the secure iCare CLINIC cloud system. Investigators review home IOP profiles every 4 weeks and use a predefined algorithm to determine whether treatment goals are met and whether glaucoma therapy should be intensified.
  • Behavioral: Standard care and smart phone-based intervention — Every 4 weeks, participants receive automated or investigator-generated smartphone text messages summarizing whether their individualized target intraocular pressure has been achieved and reminding them to adhere to prescribed eye-drop therapy. In Management Paradigm I, the feedback is based on home IOP readings from the iCare HOME device, whereas in Management Paradigm II it is based on the most recent clinic Goldmann applanation measurement. Participants reply by text with the number of missed eye-drop doses over the past 4 weeks, and clinic staff contact patients by telephone when replies or monitoring data are insufficient.

Primary Outcomes

  • IOP levels over the study period (From baseline to 30 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-18
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 142 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Collaborators: Icare Finland Oy
Principal Investigators:
  • Christopher Leung (PRINCIPAL_INVESTIGATOR) - The University of Hong Kong
Contact Information
Study Contact:
Christopher Leung
39102673
cleung21@hku.hk
Anita Yau
39102673
anitayky@hku.hk
Interventions
  • Device: Home IOP telemonitoring with smart phone-based intervention — Participants use the iCare HOME rebound tonometer to perform self-measurements of intraocular pressure at home for 30 months. After a 4-week baseline period with at least 24 measurements (early morning supine and sitting, mid-day, and evening on different days), patients continue to obtain at least six IOP measurements per week and upload readings to the secure iCare CLINIC cloud system. Investigators review home IOP profiles every 4 weeks and use a predefined algorithm to determine whether treatment goals are met and whether glaucoma therapy should be intensified.
  • Behavioral: Standard care and smart phone-based intervention — Every 4 weeks, participants receive automated or investigator-generated smartphone text messages summarizing whether their individualized target intraocular pressure has been achieved and reminding them to adhere to prescribed eye-drop therapy. In Management Paradigm I, the feedback is based on home IOP readings from the iCare HOME device, whereas in Management Paradigm II it is based on the most recent clinic Goldmann applanation measurement. Participants reply by text with the number of missed eye-drop doses over the past 4 weeks, and clinic staff contact patients by telephone when replies or monitoring data are insufficient.
Study Locations (1 sites)
HKU Eye Centre, Wong Chuk Hang, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed primary open-angle glaucoma (POAG) * Best corrected visual acuity (VA) ≥20/40 for the included eye(s) Exclusion Criteria: * IOP \>35 millimeters of mercury (mmHg) * Dry eye syndrome * Central corneal thickness \<500μm or \>600μm * Failure to complete the iCare Home certification procedure at the baseline visits * Only one eye with functional vision * Inability to perform reliable visual field (VF) * Pathological myopia (eyes with axial length≥26mm with lacquer cracks and chorioretinal atrophy) * Suboptimal quality of optical coherence tomography (OCT) images (described below in RNFL imaging) * Previous intraocular surgery or corneal refractive surgery other than uncomplicated cataract extraction * Diabetic retinopathy/maculopathy
Conditions Pulmonary Hypertension, Pulmonary Hypert...
Phase EARLY_PHASE1
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-making

Design

Study type: Interventional Phases: Early Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Percutaneous Pulmonary Artery Denervation (PADN) — \*\*PADN Procedure Steps:\*\* 1. Non-Selective Pulmonary Artery Angiography 2. PADN Ablation Target Selection 3. Hemodynamic Assessment 4. Establishment of the PADN® RF Catheter Delivery Rail 5. PADN® RF Catheter Delivery 6. Performance of the PADN Procedure While maintaining the transseptal sheath position unchanged, the PADN® RF catheter is gently and slowly withdrawn and rotated (either clockwise or counterclockwise) to bring any three of the No. 2-9 electrodes into close apposition with the three target ablation points A, B, and C. . Temperature-controlled mode is recommended for radiofrequency ablation, with the ablation temperature set to 50°C and the total ablation time set to 150 seconds. The pulmonary artery radiofrequency ablation generator will automatically start calculating the effective ablation time (ET) once the ablation temperature reaches 45°C. Ablation at each target point is considered effective when the ET reaches at least 120 seconds. 7. Completion of the PADN
  • Drug: Control group (receiving standard medical therapy alone) — Control group (receiving standard medical therapy alone)

Primary Outcomes

  • Clinical worsening event (From enrollment up to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2026-06-06
Completion: 2028-08-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xiamen Cardiovascular Hospital, Xiamen University
Contact Information
Study Contact:
Xiang CHEN, Dr
+8618033997788
seanchenx@126.com
Xiang Chen
18033997788
seanchenx@126.com
Structural Heart Disease Unit, Xiamen Cardiovacular Hospital
Interventions
  • Device: Percutaneous Pulmonary Artery Denervation (PADN) — \*\*PADN Procedure Steps:\*\* 1. Non-Selective Pulmonary Artery Angiography 2. PADN Ablation Target Selection 3. Hemodynamic Assessment 4. Establishment of the PADN® RF Catheter Delivery Rail 5. PADN® RF Catheter Delivery 6. Performance of the PADN Procedure While maintaining the transseptal sheath position unchanged, the PADN® RF catheter is gently and slowly withdrawn and rotated (either clockwise or counterclockwise) to bring any three of the No. 2-9 electrodes into close apposition with the three target ablation points A, B, and C. . Temperature-controlled mode is recommended for radiofrequency ablation, with the ablation temperature set to 50°C and the total ablation time set to 150 seconds. The pulmonary artery radiofrequency ablation generator will automatically start calculating the effective ablation time (ET) once the ablation temperature reaches 45°C. Ablation at each target point is considered effective when the ET reaches at least 120 seconds. 7. Completion of the PADN
  • Drug: Control group (receiving standard medical therapy alone) — Control group (receiving standard medical therapy alone)
Study Locations (1 sites)
Structural Heart Disease Unit, Xiamen Cardiovacular Hospital, Xiamen, Fujian 361000 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years and ≤80 years; 2. Diagnosed with pulmonary hypertension (defined as mPAP \>20 mmHg measured by right heart catheterization) at least 3 months after successful M-TEER, having received guideline-directed medical therapy (GDMT) for at least 2 months; 3. No contraindications for PADN (e.g., anatomical abnormalities of the main pulmonary artery precluding catheter placement, known pulmonary artery stenosis, uncontrolled severe arrhythmias); 4. Understands and is willing to sign the informed consent form and authorizes the use of health and study-related information; 5. Willing to comply with the treatment and follow-up schedule required by the protocol Exclusion Criteria: 1. Cardiac index (CI) \< 1.5 L/min/m²; 2. Severe renal insufficiency (creatinine clearance rate (CrCL) \< 30 mL/min); 3. Left ventricular ejection fraction (EF) \<30% on echocardiography; 4. Severe hematological disease or severe bleeding tendency (platelet count \<10×10⁹/L; severe and extensive bleeding; suspected or confirmed intracranial hemorrhage); 5. Systemic inflammatory disease, malignancy, tricuspid valve stenosis, pulmonary artery stenosis, and other cardiac diseases requiring surgical or interventional treatment; 6. Acute systemic infectious disease; 7. Poor general condition due to various systemic diseases; 8. Pulmonary veno-occlusive disease; 9. Cachexia; 10. Diagnosed with WHO Group 1, 3, 4, or 5 pulmonary hypertension; 11. Anticipated to undergo other surgical or interventional procedures within 6 months; 12. Life expectancy \<12 months; 13. Allergy to the drugs or metal materials used in the study; 14. Women who are breastfeeding, pregnant, or planning to become pregnant within one year; 15. Participation in another drug or medical device clinical trial within 3 months prior to screening; 16. Any condition deemed unsuitable for participation in this clinical trial by the investigator. \|

Renal Pelvic Denervation Pilot Trial

NCT07005050
Recruiting
Conditions Uncontrolled Hypertension
Phase NA
Enrollment 60
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The RPD Pilot trial will evaluate the safety and effectiveness of Verve Medical's RPDTM renal denervation system for hypertensive patients with uncontrolled blood pressure despite use of two medications at a therapeutic dose. The novelty of the RPDTM system relates to its placement via natural orifice into the renal pelvis (bilaterally) for delivery of radiofrequency energy to ablate the nerves that pass through the outer wall of the renal pelvis, a technique referred to as renal pelvic denervation (RPD).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: RPD — Renal Pelvic Denervation
  • Drug: Active hypertension medical therapy — Prespecified two medication regimen for control of hypertension

Primary Outcomes

  • Primary effectiveness (2 months post treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-30
Completion: 2029-03-02
Eligibility
Age: 21 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Verve Medical, Inc
Collaborators: RQM+
Contact Information
Study Contact:
Dan Merz
6126699209
dmerz@verve-medical.com
Maria El Hachem
mehachem@uabmc.edu
University of Alabama at Birmingham
Eric Judd, MD
University of Alabama at Birmingham
Interventions
  • Device: RPD — Renal Pelvic Denervation
  • Drug: Active hypertension medical therapy — Prespecified two medication regimen for control of hypertension
Study Locations (9 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35294 United States
Panoramic Health / Southwest Kidney Institute, PLC, Surprise, Arizona 85374 United States
Folio Clinical Research/Manchester Medical Group, Los Angeles, California 90045 United States
SIU School of Medicine, Springfield, Illinois 62702 United States
University of Iowa Health Care, Iowa City, Iowa 52242 United States
University of Minnesota, Minneapolis, Minnesota 55455 United States
Mayo Clinic, Rochester, Minnesota 55905 United States
DaVita Clinical Research, Las Vegas, Nevada 89107 United States
Azura Vascular Care, San Antonio, Texas 78207 United States
Eligibility Criteria
Inclusion Criteria: 1. Currently taking 2 anti-hypertensive medications (NOTE: no changes to medications allowed until after 2-month primary endpoint). \- As recommended in ACC/AHA 2017 Guideline,2 subjects are to be taking one anti-hypertensive antagonizing the renin-angiotensin system, including ACE inhibitor, ARB or renin inhibitor. Second drug should either be a calcium channel blocker (amlodipine preferred) or a thiazide diuretic. 2. Stable antihypertensive medical regimen for at least 30 days. 3. Ambulatory mean daytime SBP ≥135 mmHg. 4. Ambulatory daytime SBP \<170 and DBP \<105 mmHg. 5. Office systolic SBP ≥140 mmHg and \<180. Exclusion Criteria: 1. History of non-compliance with medical care or medical treatments. 2. History of atrial fibrillation. 3. Pregnant (verified with a urine or blood pregnancy test), breast-feeding, or planning to become pregnant. Note that all premenopausal women will be screened for pregnancy (see section 4.7.4). 4. Office SBP ≥180 and DBP ≥110 mmHg. 5. Untreated urinary tract infection. 6. Renal collecting system is compromised, such that the subject cannot undergo routine cystoscopy and retrograde pyelogram, as exemplified by duplicated collecting system, i.e., two or more ipsilateral ureters. 7. Pre-existing hydronephrosis, presence of renal calculi or ectopic, pelvic or ptotic kidney(s). 8. Receiving dialysis treatment. 9. Renal transplant recipient. 10. Presence of only one kidney, or patients with dominant unilateral kidney function with one kidney split function less than 35% 11. Polycystic kidney disease. 12. Diabetes treated with SGLT2 inhibitor and/or GLP-1 agonist 13. Persistent albuminuria (urine with 30-300 mg albumin/g creatinine) 14. Focal sclerosing glomerulosclerosis. 15. On any of the following medications: clonidine, guanfacine, or methyldopa. 16. Known secondary causes of hypertension such as adrenal disease, renal artery stenosis, renovascular hypertension. 17. Evidence in medical history or at screening of hyperaldosteronism, defined as aldosterone/renin activity \> 30 or aldosterone level \>15 ng/dL 18. Glomerulonephritis or interstitial nephritis or eGFR \<45 ml/min/1.73m2. 19. Type I diabetes mellitus. 20. Stenotic valvular heart disease for which reduction of blood pressure would be hazardous. 21. One or more episodes of orthostatic hypotension within the prior 6 months defined in section 6.6.2 as reduction of systolic blood pressure of ≥20 mmHg or diastolic blood pressure of ≥10 mm Hg within 3 minutes of standing. 22. Myocardial infarction, unstable angina, or stroke in the prior 6 months. 23. History of symptomatic heart failure 24. Echocardiographic evidence of dilated, infiltrative or hypertrophic cardiomyopathy or intracardiac mass. 25. Surgically correctable valvular heart disease. 26. Peripheral arterial disease manifest clinically by claudication or non-healing ulcers. 27. Any medical condition (including psychiatric disease) that would interfere with conducting the study or would not be in the best interest of the subject. 28. Prior diagnosis of pulmonary hypertension, use of chronic oxygen therapy or need for mechanical ventilation 29. Presence of severe obstructive sleep apnea not treated adequately by CPAP at screening. 30. On medications that affect blood pressure through off target effects, e.g., NSAIDs, steroids etc. 31. Uncorrected bleeding diathesis 32. Any clinical condition that can affect blood pressure or require the use of medications that can affect blood pressure (e.g., NSAIDs, steroids, cold remedies). 33. Life expectancy \< 24 months for any reason (investigator determination). 34. Works night shifts. 35. Upper arm circumference \> 20". 36. Subjects currently enrolled in another hypertension trial. 37. Subjects who previously received device therapy for hypertension, including renal denervation. 38. Subjects with a history of recurrent renal stones including episodes within the prior 6 months (subjects with first diagnosis of asymptomatic renal stone(s) at baseline/screening can be treated and rescreened at least one week following successful therapy of nephrolithiasis). 39. History of narcotic / opiate drug abuse 40. History of chronic pain syndrome receiving ongoing therapy with narcotic and/or opiate therapy 41. Active uroepithelial cancer 42. Artificial urinary sphincter or penile prosthesis implanted. 43. Planned medical procedures that could potentially interfere with measurement of blood pressure or assessment of any safety/effectiveness endpoints within 12 months of randomization 44. Conditions that could potentially interfere with accuracy of blood pressure measurements 45. Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults). 46. Pre-existing urological abnormalities such as hydronephrosis, ureteral vesicular reflux (congenital or acquired), neoplasia, etc. 47. Urinary tract anomalies or primary (FSGS) or secondary (e.g., Diabetic nephropathy) renal disease
Conditions Preeclampsia
Phase Not Applicable
Enrollment 2084
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening consequences are needed. Thus, the detection of women at risk of suffering PE is key to apply preventive and treatment strategies. Recently, the maternal contribution to PE based on defective decidualization that prevents the establishment of a functional maternal-fetal interface has been evidenced. The main objective of this study is to identify molecular markers or aberrant maternal-fetal cell types that can be detected early in the development of the disease in maternal-fetal interface tissue (chorionic villi + decidua) collected during gestational weeks 9 to 15. Maternal-fetal interface biopsy will be collected from women who have a recommendation for aneuploidy testing. The remaining fragment will be used for this study.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Procedure: Maternal-fetal interface biopsy and peripheral blood collection in cases group — Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.
  • Procedure: Maternal-fetal interface biopsy and peripheral blood collection in control group — Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.

Primary Outcomes

  • To charactize the molecular profile of the maternal-fetal interface between 9 and 15 weeks of gestation in healthy and preeclamptic pregnancies (From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-20
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: Not specified
Enrollment: 2084 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Carlos Simon Foundation
Principal Investigators:
  • Tamara Garrido, PhD (PRINCIPAL_INVESTIGATOR) - Fundación Carlos Simon para la investigación en salud de la mujer
Contact Information
Study Contact:
Carla Gómez, BSc, MSc
+34962938210
cgomez@fundacioncarlossimon.com
Carlos Simón, MD, PhD
Ana María Palacios Marqués
965 93 30 00
ana.palacios.marques@gmail.com
Hospital General Universitario Dr. Balmis
Interventions
  • Procedure: Maternal-fetal interface biopsy and peripheral blood collection in cases group — Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.
  • Procedure: Maternal-fetal interface biopsy and peripheral blood collection in control group — Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.
Study Locations (4 sites)
Hospital General Universitario Dr. Balmis, Alicante, Alicante Spain
Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Murcia Spain
Hospital Universitario de Canarias, Santa Cruz de Tenerife, Santa Cruz de Tenerife Spain
Hospital Universitario y Politécnico La Fe, Valencia, Valencia Spain
Eligibility Criteria
Inclusion Criteria: * Patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved. * Women over the age of 18 at the time of signing the informed consent form. * Pregnant women with a single gestation between weeks 9 and 15 of gestation who will undergo a chorionic villus biopsy according to the centre's usual clinical practice. Exclusion Criteria: * Women with multiple pregnancy. * Non-evolving pregnancies (including delayed abortion/foetal orbit).
Conditions Fetal Growth Restriction (FGR), Preterm ...
Phase Not Applicable
Enrollment 4000
Locations 2 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Pregnancy complications such as pre-eclampsia (high blood pressure during pregnancy), poor fetal growth, unexplained stillbirth, and spontaneous preterm birth are major causes of illness and death for mothers and babies in sub-Saharan Africa. These conditions, known as the Great Obstetrical Syndromes, are thought to result from problems with the development of the placenta early in pregnancy. However, there is limited information from African populations to help identify women at risk or improve prevention and treatment. This study will enroll 4,000 first-time pregnant women in Uganda before 18 weeks of pregnancy and follow them throughout pregnancy until delivery. Participants will attend routine study visits where information about their health, pregnancy, and social circumstances will be collected. Physical examinations, ultrasound scans, and blood samples will be obtained at several time points during pregnancy, and blood and placental samples will be collected at birth. Some samples will be analyzed during the study, while others will be stored for future research with appropriate ethical approval. The study will examine which clinical, biological, and social factors are associated with pregnancy complications. Researchers will use statistical methods and artificial intelligence (AI) techniques to identify patterns that may help predict which women are at increased risk of developing these conditions. The knowledge gained from this study may support the development of better screening tools and strategies for preventing pregnancy complications, improve maternal and newborn health outcomes in Uganda and other African settings, and establish a valuable biobank to support future maternal and newborn health research.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Number of Participants who Develop Pre-eclampsia (From recruitment until the date of first documented hypertension plus proteinuria or date of delivery whichever came first)
  • Number of Participants who Experience Spontaneous Preterm Birth (From recruitment to date of delivery before 37 completed weeks of gestation)
  • Number of Participants who Develop Fetal Growth Restriction (From recruitment to date of delivery)
  • Number of Participants who give birth to a stillbirth. (From recruitment to date of delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-07-25
Completion: 2026-10-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 4000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Makerere University
Principal Investigators:
  • Annettee Olivia Nakimuli, MBChB, MMED, MBA, PhD (PRINCIPAL_INVESTIGATOR) - Makerere University College of Health Sciences
Contact Information
Study Contact:
Annettee Olivia Nakimuli, MBChB, MMED, MBA, PhD
+256772471618
annettee.nakimuli@gmail.com
Moses Adroma, MBChB, MMED
+256774687070
mosesadroma@gmail.com
Sam X Ononge, MBChB, MMED, MSc, PhD
0772486301
ononge2006@yahoo.com
Mulago Specialised Women and Neonatal Hospital
Interventions
N/A
Study Locations (2 sites)
Mulago Specialised Women and Neonatal Hospital, Kampala, 22081 Uganda
Kawempe National Referral Hospital, Kampala, 3253 Uganda
Eligibility Criteria
Inclusion Criteria: * Viable singleton pregnancy at the time of the dating ultrasound scan * At less than 18 weeks of gestation by ultrasound scan * Nulliparous * Women who are indigenous Africans * Those 18 years and above * Consent to participate in the study by the participant Exclusion Criteria: \- Those who reside more 30km than from Kawempe Hospital or Mulago Hospital
Conditions Health Problems in Pregnancy, Pregnancy ...
Phase Not Applicable
Enrollment 2800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The PKUBC-WF is a prospective cohort study carried out in Weifang city of Shandong, China. The primary aim of this study is to investigate the short-term and long-term effects of pre-pregnant and prenatal exposure on maternal and child health. Data are collected regarding environmental, nutritional and lifestyle exposures as well as short-term and long-term health outcomes of mothers and their children from birth to before 18 years old. Biological samples including peripheral blood, urine, placenta, umbilical cord, cord blood, and faeces are also collected.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No Interventions — No intervention This is an observational study without any intervention

Primary Outcomes

  • Numbers and morbidity of participants with pregnancy complications (At delivery)
  • Numbers and morbidity of participants with adverse pregnancy outcomes (At delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-01
Completion: 2043-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 2800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University
Collaborators: National Natural Science Foundation of China
Principal Investigators:
  • Haijun Wang, Ph.D (PRINCIPAL_INVESTIGATOR) - Peking University
Contact Information
Study Contact:
Haijun Wang, Ph.D
86-010-82805583
whjun1@bjmu.edu.cn
Jue Liu, Ph.D
86-13426455743
jueliu@bjmu.edu.cn
Haijun Wang, Ph.D
86-010-82805583
whjun1@bjmu.edu.cn
Peking University
Interventions
  • Other: No Interventions — No intervention This is an observational study without any intervention
Study Locations (1 sites)
Peking University, Beijing, Beijing Municipality 100191 China
Eligibility Criteria
Inclusion Criteria: * Pregnant woman 1. Pregnant women, 6-13\^+6 gestational weeks 2. Resided in Weifang in the past half years and have no plan to move out after delivery 3. Pregnant women who plan to have antenatal care and delivery in Weifang maternal\&Child Hospital. 4. Pregnant women who is willing to participate in this study with informed consent * Pregnant woman's husband 1. His wife was eligible for enrollment 2. He is the biological father of the child (his wife's current pregnancy) 3. Pregnant women's husband who is willing to participate in this study with informed consent * Offspring 4. Children born to pregnant women who met the inclusion criteria after enrolling in this study. 5\. Before the age of 8 years, his/her mother provided written informed consent. 6. After 8 years old, he/she agreed to continue this study and signed the informed consent. Exclusion Criteria: * Participants who cannot communicate normally.